🚀 VC round data is live in beta, check it out!
Revvity Valuation Multiples
Discover revenue and EBITDA valuation multiples for Revvity and similar public comparables like Max Healthcare Institute, Tempus AI, Pro Medicus, Bio-Techne and more.
Revvity Overview
About Revvity
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity’s products and services are sold worldwide, with major markets in the US, Europe, and China.
Founded
1947
HQ
Employees
11.0K
Website
Financials (LTM)
EV
$13B
Revvity Financials
Revvity reported last 12-month revenue of $3B and EBITDA of $868M.
In the same LTM period, Revvity generated $2B in gross profit, $868M in EBITDA, and $595M in net income.
Revenue (LTM)
Revvity P&L
In the most recent fiscal year, Revvity reported revenue of $3B and EBITDA of $847M.
Revvity expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $868M | XXX | $847M | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 30% | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $595M | XXX | $590M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| Net Debt | — | — | $2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Revvity Stock Performance
Revvity has current market cap of $11B, and enterprise value of $13B.
Market Cap Evolution
Revvity's stock price is $93.96.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13B | $11B | 0.0% | XXX | XXX | XXX | $5.28 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRevvity Valuation Multiples
Revvity trades at 4.5x EV/Revenue multiple, and 15.0x EV/EBITDA.
EV / Revenue (LTM)
Revvity Financial Valuation Multiples
As of April 19, 2026, Revvity has market cap of $11B and EV of $13B.
Equity research analysts estimate Revvity's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Revvity has a P/E ratio of 17.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11B | XXX | $11B | XXX | XXX | XXX |
| EV (current) | $13B | XXX | $13B | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | 15.0x | XXX | 15.3x | XXX | XXX | XXX |
| EV/EBIT | 16.4x | XXX | 16.8x | XXX | XXX | XXX |
| EV/Gross Profit | 7.7x | XXX | 8.3x | XXX | XXX | XXX |
| P/E | 17.7x | XXX | 17.8x | XXX | XXX | XXX |
| EV/FCF | 24.0x | XXX | 25.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Revvity Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Revvity Margins & Growth Rates
Revvity's revenue in the last 12 month grew by 5%.
Revvity's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Revvity's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Revvity's rule of X is 42% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Revvity Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Revvity Public Comps
See public comps and valuation multiples for other Laboratory Services and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Revvity | XXX | XXX | XXX | XXX | XXX | XXX |
| Max Healthcare Institute | XXX | XXX | XXX | XXX | XXX | XXX |
| Tempus AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Pro Medicus | XXX | XXX | XXX | XXX | XXX | XXX |
| Bio-Techne | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Revvity M&A Activity
Revvity acquired XXX companies to date.
Last acquisition by Revvity was on XXXXXXXX, XXXXX. Revvity acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Revvity
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRevvity Investment Activity
Revvity invested in XXX companies to date.
Revvity made its latest investment on XXXXXXXX, XXXXX. Revvity invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Revvity
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Revvity
| When was Revvity founded? | Revvity was founded in 1947. |
| Where is Revvity headquartered? | Revvity is headquartered in United States. |
| How many employees does Revvity have? | As of today, Revvity has over 11K employees. |
| Who is the CEO of Revvity? | Revvity's CEO is Prahlad R. Singh. |
| Is Revvity publicly listed? | Yes, Revvity is a public company listed on NYSE. |
| What is the stock symbol of Revvity? | Revvity trades under RVTY ticker. |
| When did Revvity go public? | Revvity went public in 1972. |
| Who are competitors of Revvity? | Revvity main competitors are Max Healthcare Institute, Tempus AI, Pro Medicus, Bio-Techne. |
| What is the current market cap of Revvity? | Revvity's current market cap is $11B. |
| What is the current revenue of Revvity? | Revvity's last 12 months revenue is $3B. |
| What is the current revenue growth of Revvity? | Revvity revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Revvity? | Current revenue multiple of Revvity is 4.5x. |
| Is Revvity profitable? | Yes, Revvity is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Revvity? | Revvity's last 12 months EBITDA is $868M. |
| What is Revvity's EBITDA margin? | Revvity's last 12 months EBITDA margin is 30%. |
| What is the current EV/EBITDA multiple of Revvity? | Current EBITDA multiple of Revvity is 15.0x. |
| What is the current FCF of Revvity? | Revvity's last 12 months FCF is $540M. |
| What is Revvity's FCF margin? | Revvity's last 12 months FCF margin is 19%. |
| What is the current EV/FCF multiple of Revvity? | Current FCF multiple of Revvity is 24.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.